These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 22576800)
1. Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma. Faber A; Sauter A; Hoedt S; Hoermann K; Erben P; Hofheinz RD; Sommer U; Stern-Straeter J; Schultz DJ Oncol Rep; 2012 Jul; 28(1):172-8. PubMed ID: 22576800 [TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro. Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039 [TBL] [Abstract][Full Text] [Related]
3. Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC. Schultz JD; Rotunno S; Erben P; Sommer JU; Anders C; Stern-Straeter J; Hofheinz RD; Hörmann K; Sauter A Oncol Rep; 2011 Apr; 25(4):1145-51. PubMed ID: 21249321 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. Schultz JD; Sommer JU; Hoedt S; Erben P; Hofheinz RD; Faber A; Thorn C; Hörmann K; Sauter A Oncol Rep; 2012 Jan; 27(1):270-80. PubMed ID: 21993766 [TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro. Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro. Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743 [TBL] [Abstract][Full Text] [Related]
8. Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. Umbreit C; Aderhold C; Faber A; Sommer JU; Sauter A; Hofheinz RD; Stern-Sträter J; Hoermann K; Schultz JD Anticancer Res; 2013 Jun; 33(6):2457-65. PubMed ID: 23749896 [TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro. Aderhold C; Umbreit C; Faber A; Birk R; Sommer JU; Hörmann K; Schultz JD Anticancer Res; 2014 Sep; 34(9):4929-37. PubMed ID: 25202075 [TBL] [Abstract][Full Text] [Related]
10. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745 [TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134 [TBL] [Abstract][Full Text] [Related]
13. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC. Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847 [TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate. Johnson FM; Yang P; Newman RA; Donato NJ J Exp Ther Oncol; 2004 Dec; 4(4):317-25. PubMed ID: 15844661 [TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Franchi A; Santucci M; Masini E; Sardi I; Paglierani M; Gallo O Cancer; 2002 Nov; 95(9):1902-10. PubMed ID: 12404284 [TBL] [Abstract][Full Text] [Related]
16. Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma? Thomas J; Primeaux T Ann Diagn Pathol; 2012 Apr; 16(2):91-9. PubMed ID: 22197546 [TBL] [Abstract][Full Text] [Related]
17. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Begum S; Gillison ML; Nicol TL; Westra WH Clin Cancer Res; 2007 Feb; 13(4):1186-91. PubMed ID: 17317828 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Imanishi Y; Fujii M; Tokumaru Y; Tomita T; Kanke M; Kanzaki J; Kameyama K; Otani Y; Sato H Hum Pathol; 2000 Aug; 31(8):895-904. PubMed ID: 10987249 [TBL] [Abstract][Full Text] [Related]
19. Gleevec suppresses p63 expression in head and neck squamous cell carcinoma despite p63 activation by DNA-damaging agents. Ongkeko WM; An Y; Chu TS; Aguilera J; Dang CL; Wang-Rodriguez J Laryngoscope; 2006 Aug; 116(8):1390-6. PubMed ID: 16885742 [TBL] [Abstract][Full Text] [Related]
20. Papillary squamous cell carcinoma of the head and neck: frequent association with human papillomavirus infection and invasive carcinoma. Jo VY; Mills SE; Stoler MH; Stelow EB Am J Surg Pathol; 2009 Nov; 33(11):1720-4. PubMed ID: 19745700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]